News zum Sektor Gesundheit aus Hong Kong (China)

 

NEW YORK & BOSTON--(BUSINESS WIRE)--#AI--Proxima (formerly VantAI), the AI-native biotech company pioneering the next generation of AI-driven drug discovery for proximity therapeutics, today announced an oversubscribed $80M seed financing. The round was led by DCVC, with participation from NVentures (NVIDIA's venture capital arm), Braidwell, Roivant, AIX Ventures, Yosemite, Magnetic Ventures, Alexandria Venture Investments, Modi Ventures, and additional strategic and institutional investors. As part of the financing, the company has rebranded from VantAI to Proxima to reflect its singular focus on building out both the technology and data layer needed to unlock proximity-based therapeutics. These next generation medicines work by controlling how proteins interact with one another, rather than simply inhibiting or activating a single target, and represent a superset that includes modalities such as molecular glues and PROTACs that have the potential to unlock historically undruggable disease targets. The ...

Stock | Potential Upside to Target PriceAlibaba (BABA.US) | 16.5%YANGTZE POWER (600900.SH) | 27.6%CONTEMPORARY AMPEREX (300750.SZ) | 32.7%DUALITYBIO-B (09606.HK) | 39.3%ESPRESSIF (688018.SH) | 26.9%HKEX (00388.HK) | 19.5%HKT-SS (06823.HK) | 10.7%NARI (600406.SH) | 12.3%PING AN (02318.HK) | 26.8%INOVANCE TECH (300124.SZ) | 22.5%S......

BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that Chief Executive Officer Ivor Elrifi will deliver a corporate presentation at the 9th Annual Neuroscience Innovation Forum, organized by Sachs Associates. The presentation is scheduled for 2:00 PM PT on January 11, 2026, at the Marines' Memorial Club in San Francisco, California, during J.P. Morgan Healthcare Conference Week....

HKEX (00388.HK) has announced the launch of six new stock option classes effective on Monday, January 19, 2026, building on the strong momentum in the single stock options market and offering more choices to investors.These stocks include ZIJIN GOLD INTL (02259.HK), WUXI APPTEC (02359.HK), BEONE MEDICINES (06160.HK), LAOPU GOLD ......

At close, HSI dropped 309 pts or 1.2% to 26,149. HSTI dropped 60 pts or 1.0% to 5,678. HSCEI fell 99 pts or 1.1% to 9,039. Market turnover reached $268.27 billion.Active Heavyweights:MEITUAN (03690.HK) closed at $101, down 3.3%BABA (09988.HK) closed at $142.6, down 2.3%TENCENT (00700.HK) closed at $616, down 1.4%PING AN (02318.H......

At midday close, HSI dropped 322 pts or 1.2% to 26,136. HSTI dropped 64 pts or 1.1% to 5,673. HSCEI fell 103 pts or 1.1% to 9,034.Active Heavyweights:MEITUAN (03690.HK) closed at $101.6, down 2.8%XIAOMI (01810.HK) closed at $37.48, down 1.8%TENCENT (00700.HK) closed at $614, down 1.7%BABA (09988.HK) closed at $143.7, down 1.5%PI......

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

TheraVectys SA is considering an initial public offering in Hong Kong, according to people familiar with the matter, a rare move for a non-Chinese biotech firm despite a wave of listings in the Asian financial hub....

The CSPC market is poised for strong, double-digit growth, driven by aging demographics, improved screening, and strategic treatment advancements. While cost and access challenges persist, emerging therapies such as TRUQAP (AstraZeneca), TAVT-45 (Tavanta Therapeutics), Saruparib......

Hong Kong's biotech fundraising momentum is expect to extend into 2026, as licensing deals and strong post-initial public offering (IPO) trading last year persuaded investors that China's drug developers are worth backing again – even before they generate revenue. “Chinese innovation drugs expanding into overseas markets have become the industry mainstream, indicating the domestic innovation sector has entered its harvest phase,” said Felix Huang, head of equity at Oakwise Capital. “New trends......

CICC released its outlook report for 2026, listing its top picks for Hong Kong stocks:StocksTENCENT (00700.HK)BABA-W (09988.HK)CHINA MOBILE (00941.HK)CNOOC (00883.HK)NTES-S (09999.HK)SMIC (00981.HK)ZIJIN GOLD INTL (02259.HK)BYD COMPANY (01211.HK)AKESO (09926.HK)CATL (03750.HK)HAIER SMARTHOME (06690.HK)SKB BIO-B (06990.HK) JIANGX......

Castle Biosciences surged 77.9% after a Zacks upgrade, highlighting how the firm's stock picks outpaced the broader market in recent months....

BOSTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the submission of its seventh annual Development Safety Update Report (DSUR) to the U.S. Food and Drug Administration (FDA). This DSUR (September 21, 2024, to September 2, 2025), reports no drug-related serious adverse events after a cumulative exposure of 37.4 patient-years, highlighting the safety and tolerability data profile of intranasal foralumab in treating neuroinflammatory diseases, including non-active secondary progressive multiple sclerosis (naSPMS), multiple system atrophy and Alzheimer's Disease (AD)....

GRAND PHARMA (00512.HK) entered into a product cooperation agreement with Pediatrix Therapeutics, as announced by GRAND PHARMA. The Group will acquire the exclusive commercialization rights in Mainland China through cooperative channels and the non-exclusive commercialization rights in Hong Kong Special Administrative Region for......

SIMCERE PHARMA (02096.HK) announced that the Group’s independently developed Bispecific Antibody-Drug Conjugate (BsADC) investigational new drug candidate, SIM0610, had received the Clinical Trial Approval issued by the National Medical Products Administration of China, and is intended to be evaluated in patients with loca......

The HSI concluded at 25,774, down 27 points or 0.11%. The HSCEI dipped 25 points or 0.29% to close at 8,913. The HSTECH lost 37 points or 0.69% to end at 5,488. Trading was muted ahead of the long holiday, with total turnover reaching HK$157.131 billion.Techs jumbled. KUAISHOU-W (01024.HK), whose live-streaming function was unde......

The HSI concluded the midday up 47 points or 0.18% at 25,848. The HSCEI climbed 9 points or 0.11% to 8,949. The HSTECH dipped 22 points or 0.42% to 5,503. The market's half-day turnover amounted to HKD87.289 billion.Tech stocks showed mixed performance. KUAISHOU-W (01024.HK) slid 3.6% at midday, making it the worst-performin......

Blue-chip CSPC PHARMA (01093.HK) opened 0.6% higher today (23rd) before extending its gains to rally as much as 6.2% peaking at HK$8.76. It last posted at HK$8.67, up 5.09%, with a trading volume of 119 million shares, involving HK$1.022 billion.CSPC PHARMA Executive Director and Chairman Cai Dongchen increased his stake in the ......

PARIS, FRANCE; 22 DECEMBER 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today an exclusive licensing agreement for global rights outside of Greater China, for SIM0613, an antibody-drug conjugate (ADC) with best-in-class potential. Targeting the LRRC15 protein, SIM0613 is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs....

BEIJING (dpa-AFX) - Simcere Pharmaceutical Group Ltd. (2096.HK, SMHGF), on Monday, announced that a subsidiary, Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., has entered into an exclusive lice......